Role of Radiation Therapy in Cutaneous Melanoma

Clinics in Plastic Surgery

Volumn 37, Issue 1, 2010, Pages 147-160

  Shuff, Jaime H ^a   Siker, Malika L ^a   Daly, Mackenzie D ^a   Schultz, Christopher J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adjuvant treatment; Cutaneous melanoma; Palliative radiation; Postoperative radiation; Radiation therapy

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; GANGLIOSIDE VACCINE; INTERFERON; KEYHOLE LIMPET HEMOCYANIN VACCINE; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; APPLICATION SITE DESQUAMATION; APPLICATION SITE ERYTHEMA; ARM EDEMA; ARTHROPATHY; BONE NECROSIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG MEGADOSE; HEARING IMPAIRMENT; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MELANOMA; MORBIDITY; MUCOSA INFLAMMATION; NEURALGIA; OTALGIA; PARESIS; PAROTID GLAND DISEASE; PATIENT SELECTION; POSTOPERATIVE CARE; PROGNOSIS; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; SKIN DISCOMFORT; SKIN INDURATION; SKIN TOXICITY; SKIN ULCER; STEREOTACTIC RADIOSURGERY; SUBCUTANEOUS FAT DISORDER; SURVIVAL RATE; SURVIVAL TIME; THYROID DISEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MELANOMA; PALLIATIVE CARE; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS;

EID: 70449432830     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2009.07.007     Document Type: Review

References (84)

1. Jemal A., Siegal R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Beral V., Evans S., Shaw H., et al. Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol 109 (1983) 165-172
3. Gellin G.A., Kopf A.W., and Garfinkel L. Malignant melanoma. A controlled-study of possibly associated factors. Arch Dermatol 99 (1969) 43-48
4. English D.R., Armstrong B.K., Kricker A., et al. Sunlight and cancer. Cancer Causes Control 8 (1997) 271-283
5. Tucker M.A., and Goldstein A.M. Melanoma etiology: where are we?. Oncogene 22 (2003) 3042-3052
6. Cho E., Rosner B.A., Feskanich D., et al. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 23 (2005) 2669-2675
7. Bliss J.M., Ford D., Swerdlow A.J., et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case controlled studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62 (1995) 367-376
8. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
9. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alpha-2b in high-risk melanoma: first analysis of intergroup trial E1690/s9111/c9190. J Clin Oncol 18 (2000) 2444-2458
10. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
11. Perales M., and Wolchok J.D. Melanoma vaccines. Cancer Invest 20 (2002) 1012-1026
12. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 (2002) 438-449
13. Tsao H., Atkins M.B., and Sober A.J. Management of cutaneous melanoma. N Engl J Med 351 (2004) 998-1012
14. Simpson F.E. Radium in skin diseases. JAMA 61 (1913) 80-83
15. Coley W.B., and Hoquet J.P. Metastatic cancer, with a report of 91 patients. Ann Surg 64 (1916) 206-241
16. Adair F.E. Treatment of melanoma. Surg Gynecol Obstet 62 (1936) 406-409
17. Paterson R. Classification of tumours in relation to radiosensitivity. Br J Radiol 6 (1933) 218-233
18. Ellis F. The radiosensitivity of malignant melanoma. Br J Radiol 12 (1939) 327-352
19. Nitter L. The treatment of malignant melanoma with special reference to the possible effect of radiotherapy. Acta Radiol 46 (1956) 547-562
20. Tod M.C. Radiological treatment of malignant melanoma. Br J Radiol 19 (1946) 223-229
21. Dickson R.J. Malignant melanoma. A combined surgical and radiotherapeutic approach. Am J Roentgenol 79 (1958) 1063-1070
22. Hellriegel W. Radiation therapy of primary and metastatic melanoma. Ann N Y Acad Sci 100 (1963) 132-141
23. Owen A.K. A case of melanosarcoma treated with roentgen rays. Am J Roentgenol 11 (1924) 335-336
24. Evans W.A., and Leucutia T. The treatment of metastatic tumors of skin: pigmented moles and melanomas. Am J Roentgenol 26 (1931) 236-259
25. Anderson H.F., and Simpson C.A. Pigmented moles and their treatment. Am J Roentgenol 33 (1935) 54-58
26. Harwood A.R., and Cummings B.J. Radiotherapy for malignant melanoma: a re-appraisal. Cancer Treat Rev 8 (1981) 271-282
27. Jenrette J.M. Malignant melanoma: the role of radiation therapy revisited. Semin Oncol 23 (1996) 759-762
28. Dewey D.L. The radiosensitivity of melanoma cells in culture. Br J Radiol 44 (1971) 816-817
29. Barranco S.C., Romsdahl M.M., and Humphrey R.M. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31 (1971) 830-833
30. Hornsey S. The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients. Br J Radiol 51 (1978) 905-909
31. Habermalz H.J., and Fischer J.J. Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer 38 (1976) 2258-2262
32. Adams J.S., Habeshw T., and Kirk J. Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 55 (1982) 605-607
33. Stevens G., and McKay M.J. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol 7 (2006) 575-583
34. McKay M.J., and Kefford R.F. The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by the differential induction or rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys 31 (1995) 345-352
35. Rofstad E.K. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 52 (1992) 4453-4457
36. Overgaard J., Overgaard M., Hansen P.V., et al. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5 (1986) 183-192
37. Bentzen S.M., Overgaard J., Thames H.D., et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 16 (1989) 169-182
38. Overgaard J., von der Maase H., and Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Biol Phys 11 (1985) 1837-1839
39. Overgaard J., Gonzalez Gonzalez D., Hulshof M.C., et al. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345 (1995) 540-543
40. Ang K.K., Peters L.J., Weber R.S., et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 30 (1994) 795-798
41. Stevens G., Thompson J.F., Firth I., et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 88 (2000) 88-94
42. Chang D.T., Amdur R.J., Morris C.G., et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 66 4 (2006) 1051-1055
43. Sause W.T., Cooper J.S., Rush S., et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20 (1991) 429-432
44. Balch C.M., Soong S.J., Smith T., et al. Long term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 8 2 (2001) 101-108
45. Urist M.M., Balch C.M., Soong S., et al. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 55 6 (1985) 1398-1402
46. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
47. Balch C.M., Wilkerson J.A., Murad T.M., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 45 (1980) 3012-3017
48. McGovern V.J., Shaw H.M., Milton G.W., et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 6 (1982) 399-407
49. Buzaid A.C., Ross M.I., Balch C.M., et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15 (1997) 1039-1051
50. Balch C.M., Soong S.J., Murad T.M., et al. A multifactorial analysis of melanoma: prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193 (1981) 377-388
51. O'Brien C.J., Coates A.S., Peterson-Schaefer K., et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 162 (1991) 310-314
52. Calabro A., Singletary S.E., and Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124 (1989) 1051-1055
53. Lee R.J., Gibbs J.F., Proulx G.M., et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 46 2 (2000) 467-474
54. Monsour P.D., Sause W.T., Avent J.M., et al. Local control following therapeutic nodal dissection for melanoma. J Surg Oncol 54 (1993) 18-22
55. Shen P., Wanek L.A., and Morton D.L. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanoma?. Ann Surg Oncol 7 (2000) 554-559
56. Bowsher W.G., Taylor B.A., and Hughes L.E. Morbidity, mortality, and local recurrence following regional node dissection for melanoma. Br J Surg 73 (1986) 906-908
57. Creagan E.T., Cupps R.E., Ivins J.C., et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. Cancer 42 (1978) 2206-2210
58. Ballo M.T., Strom E.A., Zagars G.K., et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52 4 (2002) 964-972
59. Bonnen M.D., Ballo M.T., Garden A.S., et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 100 2 (2004) 383-389
60. Verma S., Quirt I., McCready D., et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106 7 (2006) 1431-1442
61. Creagan E.T., Dalton R.J., Ahmann D.L., et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13 (1995) 2776-2783
62. Conill C., Jorcano S., Domingo-Domenech J., et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 17 5 (2007) 304-309
63. Hazard L.J., Sause W.T., and Noyes R.D. Combined adjuvant radiation and interferon-alpha 2B therapy in high- risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 52 3 (2002) 796-800
64. Gyorki D.E., Ainslie J., Joon M.L., et al. Concurrent adjuvant radiotherapy and interferon-alpha 2b for resected high risk stage III melanoma-a retrospective single centre study. Melanoma Res 14 (2004) 223-230
65. Olivier K.R., Schild S.E., Morris C.G., et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110 8 (2007) 1791-1795
66. Seegenschmiedt M.H., Ludwig K., Altendorf-Hofmann A., et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44 3 (1999) 607-618
67. Douglas J.G., and Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 29 5 (2002) 518-524
68. Schouten L.J., Rutten J., Huveneers H.A., et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 (2002) 2698-2705
69. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12 7 (2006) 2353s-2358s
70. Wen P.Y., Black P.M., and Loeffler J.S. Metastatic brain cancer. In: Devita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th edition (2001), Lippincott, Williams & Wilkins, Philadelphia 2655-2670
71. Broadbent A.M., Hruby G., Tin M.M., et al. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol 71 (2004) 259-265
72. Lagerwaard F.J., Levendag P.C., Nowak P.J., et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43 (1999) 795-803
73. Meier S., Baumert B.G., Maier T., et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 27 (2004) 145-149
74. Brega K., Robinson W.A., Winston K., et al. Surgical treatment of brain metastases in malignant melanoma. Cancer 66 (1990) 2105-2110
75. Samlowski W.E., Watson G.A., Wang M., et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109 9 (2007) 1855-1862
76. Mathieu D., Kondziolka D., Cooper P.B., et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60 (2007) 471-482
77. Boogerd W., de Gast G.C., and Otilia D. Temozolomide in advanced malignant melanoma with small brain metastases. Cancer 109 2 (2007) 3106-3212
78. Atkins M.B., Sosman J.A., Agarwala S.A., et al. Temozolomide, thalidomide and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. Cancer 113 8 (2008) 2139-2145
79. Bastiaannet E., Beukema J.C., and Hoekstra H.J. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev 31 (2005) 18-26
80. Ballo M.T., Bonnen M.D., Garden A.S., et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97 (2003) 1789-1796
81. Burmeister B.H., Smithers B.M., Spry N., et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 72 (2002) 344-348
82. Beadle B.M., Guadagnolo B.A., Ballo M.T., et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 73 5 (2009) 1376-1382
83. Mack L.A., and McKinnon J.G. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 86 (2004) 189-199
84. Ballo M.T., Gunar K.Z., Jeffery E.G., et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases form melanoma. Ann Surg Oncol 11 (2004) 1079-1084